Strain Name:

B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax

Availability:

Cryopreserved - Ready for recovery     Available at the JAX MMRRC

Use Restrictions Apply, see Terms of Use
This strain is now distributed by the Mutant Mouse Regional Resource Center. Please refer to the Mutant Mouse Regional Resource Center (MMRRC) for ordering information and strain details on B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax MMRRC Stock Number 034846.
As a designated MMRRC center, The Jackson Laboratory will continue to distribute these mice at the same high health and
quality standards but ordering is exclusively provided through the MMRRC.
These TetAPPswe/ind mice (formerly JAX Stock No. 007052) express human APP bearing the Swedish and Indiana mutations in a tet-responsive manner. Amyloid pathology is observed when the transgene is expressed. This strain has been shown to be useful in studies correlating temporal expression of mutant APP expression with Alzheimer's-like amyloid pathology.

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Former Names B6.Cg-Tg(tetO-APPSwInd)107Dbo/J    (Changed: 11-AUG-11 )
Type Congenic; Mutant Strain; Transgenic;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Specieslaboratory mouse
Generation?+F0pN1
Generation Definitions
 
Donating InvestigatorDr. David R Borchelt,   University of Florida

Description
Hemizygotes for this tetO-APPswe/ind transgene are viable and fertile. These transgenic mice express a chimeric mouse/human amyloid precursor protein (APP695) bearing the Swedish (KM570/571NL) and Indiana (V617F) mutations associated with Alzheimer's disease (APP695swe/ind) under the control of a tetracycline-responsive promoter element (TRE; tetO). When hemizygotes are bred with another transgenic mouse expressing either reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the regulation of a tissue-specific promoter, APP695swe/ind expression in the target tissue of the bitransgenic offspring can be regulated with the tetracycline analog doxycycline (dox) in the resulting double mutant offspring. These tetO-APPswe/ind transgenic mice may be useful in studies of Alzheimer's disease and other neurodegenerative diseases.

For example, when bred to a strain expressing tTA in brain tissues (Tg(Camk2a-tTA)1Mmay), bi-transgenic offspring show 10-30 fold greater transgenic APP695swe/ind protein expression than endogenous levels and nearly complete suppression following dox treatment. The donating investigators report some differences in APP695swe/ind expression in bi-transgenic offspring dependent upon which APP695swe/ind founder line was used; line 885 (B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax) shows the highest APP695swe/ind expression with greater dox requirements for transgene suppression, line 102 (B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax) has the greatest sensitivity to dox, and line 107 (B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax) and line 18 are similarly intermediate.

Note that tet alone may affect neuronal degeneration and behavioral phenotypes, depending on the genetic background used (see Han et al, J. Neurosci., 2012).

In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. It should be noted that the phenotype could vary from that originally described. We will modify the strain description if necessary as published results become available.

Development
The mouse amyloid beta (A4) precursor protein (App) sequence was first modified to contain a humanized amyloid-beta (Abeta) domain. This mouse/human chimeric APP (called mo/huAPP695 or APP695) was further mutated to incorporate the Swedish (KM570/571NL) and Indiana (V617F) mutations associated with Alzheimer's disease. This APP695swe/ind sequence was placed downstream of the tetracycline-responsive (TRE;tetO) promoter and mouse prion protein exons 1-2. The complete tetracycline-responsive APP695swe/ind transgene (tet-APPswe/ind) was injected into the pronucleus of fertilized eggs from (C57BL/6J x C3HeJ) F1 matings. Transgene positive founders (line 107) were bred to transgenic Camk2a-tTA mice (B6;CBA-Tg(Camk2a-tTA)1Mmay/J) on a B6;CBA mixed genetic background. After 3-4 generations of brother-sister matings, mice harboring only the tet-APPswe/ind transgene were selected and backcrossed to C57BL/6 for at least 10 generations prior to arrival at the MMRRC at The Jackson Laboratory.

Related Strains

Alzheimer's Disease Models
005987   129-Achetm1Loc/J
006409   129S1.129(Cg)-Tg(APPSw)40Btla/Mmjax
008077   129S1/Sv-Bchetm1Loc/J
016198   129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ
014556   129S6/SvEv-Apoetm4Mae/J
006555   A.129(B6)-Tg(APPSw)40Btla/Mmjax
005708   B6.129-Apbb1tm1Quhu/J
004714   B6.129-Bace1tm1Pcw/J
004098   B6.129-Klc1tm1Gsn/J
004193   B6.129-Psen1tm1Mpm/J
003615   B6.129-Psen1tm1Shn/J
005300   B6.129-Tg(APPSw)40Btla/Mmjax
005617   B6.129P-Psen2tm1Bdes/J
002609   B6.129P2-Nos2tm1Lau/J
007685   B6.129P2-Psen1tm1Vln/J
007999   B6.129P2-Sorl1Gt(Ex255)Byg/J
008087   B6.129S1-Bchetm1Loc/J
002509   B6.129S2-Plautm1Mlg/J
005301   B6.129S2-Tg(APP)8.9Btla/J
004163   B6.129S4-Cdk5r1tm1Lht/J
010959   B6.129S4-Grk5tm1Rjl/J
010960   B6.129S4-Grk5tm2Rjl/J
002213   B6.129S4-Ngfrtm1Jae/J
006406   B6.129S4-Tg(APPSwLon)96Btla/Mmjax
006469   B6.129S4-Tg(PSEN1H163R)G9Btla/J
012564   B6.129S5-Dhcr24tm1Lex/SbpaJ
004142   B6.129S7-Aplp2tm1Dbo/J
004133   B6.129S7-Apptm1Dbo/J
007251   B6.129X1-Mapttm1Hnd/J
013040   B6.Cg-Apoetm1Unc Ins2Akita/J
005642   B6.Cg-Clutm1Jakh/J
005491   B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
009126   B6.Cg-Nos2tm1Lau Tg(Thy1-APPSwDutIowa)BWevn/Mmjax
005866   B6.Cg-Tg(APP695)3Dbo Tg(PSEN1dE9)S9Dbo/Mmjax
008730   B6.Cg-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax
005864   B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax
007575   B6.Cg-Tg(CAG-Ngb,-EGFP)1Dgrn/J
016197   B6.Cg-Tg(CAG-OTC/CAT)4033Prab/J
005855   B6.Cg-Tg(Camk2a-Prkaca)426Tabe/J
007004   B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ
004996   B6.Cg-Tg(DBH-Gal)1923Stei/J
007673   B6.Cg-Tg(Gad1-EGFP)3Gfng/J
004662   B6.Cg-Tg(PDGFB-APP)5Lms/J
006293   B6.Cg-Tg(PDGFB-APPSwInd)20Lms/2Mmjax
006006   B6.Cg-Tg(Prnp-APP)A-2Dbo/J
008596   B6.Cg-Tg(Prnp-Abca1)EHol/J
006005   B6.Cg-Tg(Prnp-App/APPswe)E1-2Dbo/Mmjax
007180   B6.Cg-Tg(Prnp-ITM2B/APP695*40)1Emcg/J
007182   B6.Cg-Tg(Prnp-ITM2B/APP695*42)A12Emcg/J
005999   B6.Cg-Tg(SBE/TK-luc)7Twc/J
012597   B6.Cg-Tg(Thy1-COL25A1)861Yfu/J
007051   B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax
007049   B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax
009337   B6.FVB-Tg(Prnp-RTN3)2Yanr/J
006394   B6;129-Apba2tm1Sud Apba3tm1Sud Apba1tm1Sud/J
008364   B6;129-Chattm1(cre/ERT)Nat/J
008476   B6;129-Ncstntm1Sud/J
004807   B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax
007605   B6;129P-Psen1tm1Vln/J
005618   B6;129P2-Bace2tm1Bdes/J
008333   B6;129P2-Dldtm1Ptl/J
002596   B6;129P2-Nos2tm1Lau/J
003822   B6;129S-Psen1tm1Shn/J
012639   B6;129S4-Mapttm3(HDAC2)Jae/J
012869   B6;129S6-Apbb2tm1Her/J
006410   B6;129S6-Chattm2(cre)Lowl/J
005993   B6;129S6-Pcsk9tm1Jdh/J
008636   B6;C-Tg(Prnp-APP695*/EYFP)49Gsn/J
007002   B6;C3-Tg(Prnp-ITM2B/APP695*42)A12Emcg/Mmjax
008169   B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J
000231   B6;C3Fe a/a-Csf1op/J
008850   B6;SJL-Tg(Mt1-LDLR)93-4Reh/AgnJ
003378   B6C3-Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J
004462   B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax
003741   B6D2-Tg(Prnp-MAPT)43Vle/J
016556   B6N.129-Ptpn5tm1Pjlo/J
018957   B6N.129S6(B6)-Chattm2(cre)Lowl/J
024841   B6N.Cg-Tg(Prnp-MAPT*P301S)PS19Vle/J
006554   B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax
012621   C.129S(B6)-Chrna3tm1.1Hwrt/J
002328   C.129S2-Plautm1Mlg/J
003375   C3B6-Tg(APP695)3Dbo/Mmjax
005087   C57BL/6-Tg(Camk2a-IDE)1Selk/J
005086   C57BL/6-Tg(Camk2a-MME)3Selk/J
008833   C57BL/6-Tg(Camk2a-UBB)3413-1Fwvl/J
007027   C57BL/6-Tg(Thy1-APPSwDutIowa)BWevn/Mmjax
010800   C57BL/6-Tg(Thy1-PTGS2)300Kand/J
010703   C57BL/6-Tg(Thy1-PTGS2)303Kand/J
005706   C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J
006618   C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J
007677   CB6-Tg(Gad1-EGFP)G42Zjh/J
007072   CByJ.129P2(B6)-Nos2tm1Lau/J
006472   D2.129(B6)-Tg(APPSw)40Btla/Mmjax
007067   D2.129P2(B6)-Apoetm1Unc/J
013719   D2.Cg-Apoetm1Unc Ins2Akita/J
003718   FVB-Tg(GadGFP)45704Swn/J
013732   FVB-Tg(NPEPPS)1Skar/J
013156   FVB-Tg(tetO-CDK5R1*)1Vln/J
015815   FVB-Tg(tetO-MAPT*P301L)#Kha/JlwsJ
002329   FVB.129S2-Plautm1Mlg/J
003753   FVB/N-Tg(Eno2CDK5R1)1Jdm/J
006143   FVB/N-Tg(Thy1-cre)1Vln/J
008051   NOD.129P2(B6)-Ctsbtm1Jde/RclJ
008390   STOCK Apptm1Sud/J
012640   STOCK Hdac2tm1.2Rdp/J
004808   STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
004779   STOCK Mapttm1(EGFP)Klt/J
014092   STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J
014544   STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/J
View Alzheimer's Disease Models     (109 strains)

View Strains carrying other alleles of APP695     (10 strains)

Strains carrying other alleles of tetO
008079   129S-Ppargtm2Yba/J
016178   B6(Cg)-Tg(tetO-Cry2)3Jt/J
016176   B6(Cg)-Tg(tetO-Per2)2Jt/J
023757   B6(Cg)-Tg(tetO-tetX,lacZ)1Gogo/UmriJ
009602   B6.129S4(Cg)-Kcnn2tm2Jpad/J
009603   B6.129S4-Kcnn3tm1Jpad/J
023910   B6.Cg-Col1a1tm1(tetO-Lin28a)Gqda/J
023911   B6.Cg-Col1a1tm2(tetO-LIN28B)Gqda/J
023912   B6.Cg-Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/J
017983   B6.Cg-Col1a1tm9(tetO-Dnmt3b_i1)Jae Gt(ROSA)26Sortm1(rtTA*M2)Jae/J
014588   B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm6(tetO-MSI2)Jae/J
023749   B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Tg(tetO-Pou5f1,-Sox2,-Klf4,-Myc)1Srn/J
014648   B6.Cg-Gt(ROSA)26Sortm37(H1/tetO-RNAi:Taz)Arte/ZkhuJ
006361   B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J
016998   B6.Cg-Tg(TetO-Axin1,EGFP)TA6Cos/J
003762   B6.Cg-Tg(tetFosb)4468Nes/J
007051   B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax
007049   B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax
007618   B6.Cg-Tg(tetO-Arntl)1Jt/J
017555   B6.Cg-Tg(tetO-CALY)5Cber/J
024114   B6.Cg-Tg(tetO-CHRM4*)2Blr/J
008277   B6.Cg-Tg(tetO-Clockm1Jt)CL57Jt/J
008468   B6.Cg-Tg(tetO-DTA)1Gfi/J
017791   B6.Cg-Tg(tetO-Hamp)2181Nca/J
009344   B6.Cg-Tg(tetO-Ifng)184Pop/J
009136   B6.Cg-Tg(tetO-Kcnj2,lacZ)1Gogo/J
013583   B6.Cg-Tg(tetO-LRRK2)C7874Cai/J
020652   B6.Cg-Tg(tetO-Mif)279Aren/J
017331   B6.Cg-Tg(tetO-Ppp3ca*)11255Kndl/J
017332   B6.Cg-Tg(tetO-Ppp3ca*)13967Kndl/J
017330   B6.Cg-Tg(tetO-TAg*)175Kndl/J
006234   B6.Cg-Tg(tetO-cre)1Jaw/J
005738   B6.FVB-Tg(tetO-EGFP,-Tgfbr2)8Mcle/J
021025   B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm1(tetO-cre)Haho/J
006911   B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm2(tetO-Pou5f1)Jae/J
011001   B6;129S4-Col1a1tm1(tetO-Pou5f1,-Klf4,-Sox2,-Myc)Hoch/J
016836   B6;129S4-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm7(tetO-HIST1H2BJ/GFP)Jae/J
012433   B6;C3-Tg(ACTA1-rtTA,tetO-cre)102Monk/J
002709   B6;C3-Tg(TettTALuc)1Dgs/J
023598   B6;C3-Tg(tetO-AIMP2)630Tmd/J
023642   B6;C3-Tg(tetO-AIMP2)634Tmd/J
016841   B6;C3-Tg(tetO-TARDBP)12Vle/J
014650   B6;C3-Tg(tetO-TARDBP*)4Vle/J
012450   B6;D2-Tg(tetO-SNCA)1Cai/J
008344   B6;DBA-Tg(Fos-tTA,Fos-EGFP*)1Mmay Tg(tetO-lacZ,tTA*)1Mmay/J
024742   B6;DBA-Tg(tetO-GCaMP6s)2Niell/J
024088   B6;FVB-Tg(tetO-AML1/ETO)8Dzh/J
008082   B6;SJL-Tg(Tagln-tTA)1Mrab Tg(tetO-Mcpt1)1Mrab/J
010575   B6;SJL-Tg(tetO-Egfr*)2-9Jek/J
010577   B6;SJL-Tg(tetO-Erbb2*)8-4Jek/J
002621   B6;SJL-Tg(tetop-lacZ)2Mam/J
006004   B6C3-Tg(tetO-APPSwInd)885Dbo/Mmjax
016976   B6C3-Tg(tetO-SNCA*A53T)33Vle/J
018913   B6N.Cg-Tg(tetO-GFP,-lacZ)G3Rsp/J
006244   C.Cg-Tg(tetO-cre)1Jaw/J
017719   C3HeB/FeJ-Tg(tetO-TAg)1Efr/J
017955   C57BL/6-Tg(Gfap-rtTA,tetO-MAOB,-lacZ)1Jkan/J
025487   C57BL/6-Tg(tetO-Aimp1)29872Mcla/J
005706   C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J
006618   C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J
017613   C57BL/6-Tg(tetO-Cdkn1b)1Scpr/J
013729   C57BL/6-Tg(tetO-EDN1,-lacZ)9Mhus/J
016260   C57BL/6-Tg(tetO-Fbxl21)38Jt/J
016179   C57BL/6-Tg(tetO-Fbxl21*)11Jt/J
010713   C57BL/6-Tg(tetO-GFP/tetX)5696Stl/J
013728   C57BL/6-Tg(tetO-NOS2,-lacZ)240iMhus/J
016181   C57BL/6-Tg(tetO-Nr1d1)1Schb/J
016581   C57BL/6J-Tg(tetO-Btrc*)1Jt/J
008278   C57BL/6J-Tg(tetO-Clock)1Jt/J
024898   C57BL/6J-Tg(tetO-EGFP/Rpl10a)5aReij/J
016580   C57BL/6J-Tg(tetO-Usf1)2Jt/J
021065   FVB(C)-Tg(tetO-Npc1/YFP)1Mps/J
017542   FVB-Tg(Myh6/tetO-ATP2B4)1Jmol/J
016571   FVB-Tg(Myh6/tetO-Gata6)2Jmol/J
014155   FVB-Tg(Myh6/tetO-Itpr1)22.3Jmol/J
014153   FVB-Tg(Myh6/tetO-Itpr2)3.11Jmol/J
014154   FVB-Tg(Myh6/tetO-Itpr2)4.9Jmol/J
012684   FVB-Tg(Myh6/tetO-POSTN)22.1Jmol/J
010580   FVB-Tg(Myh6/tetO-PRKCA*)1Jmk/J
013156   FVB-Tg(tetO-CDK5R1*)1Vln/J
013777   FVB-Tg(tetO-Cacna1g)1Jmol/J
013778   FVB-Tg(tetO-Cacnb2)1Jmol/J
013779   FVB-Tg(tetO-Cacnb2)2Jmol/J
013780   FVB-Tg(tetO-Cib1)1Jmol/J
010578   FVB-Tg(tetO-Dusp6)1Jmol/J
017333   FVB-Tg(tetO-Gnai2*,-lacZ)382Kndl/J
008685   FVB-Tg(tetO-Kdr*)4377.5Rwng/J
023397   FVB-Tg(tetO-Lmnb1)AF1Yfu/J
015815   FVB-Tg(tetO-MAPT*P301L)#Kha/JlwsJ
008695   FVB-Tg(tetO-MET)23Rwng/J
012387   FVB-Tg(tetO-Ppargc1a)1Dpk/J
012385   FVB-Tg(tetO-Ppargc1b)7Dpk/J
022979   FVB-Tg(tetO-Thbs4)17.7Jmol/J
006439   FVB-Tg(tetO/CMV-KRAS*G12C)9.1Msmi/J
019038   FVB.Cg-Tg(tetO-GLI1)10Rup/Mmjax
019039   FVB.Cg-Tg(tetO-KLF4)32831Rup/Mmjax
008244   FVB.Cg-Tg(tetO-cre)1Jaw/J
012459   FVB/N-Tg(Myh6*/tetO-Capn1)L2Gwd/J
005941   FVB/N-Tg(tetO-Aurkb,lacZ)41Kra/J
006202   FVB/N-Tg(tetO-BCR/ABL1)2Dgt/J
014547   FVB/N-Tg(tetO-Fasl)BDepa/J
025672   FVB/N-Tg(tetO-Fgfr2b/Igh)1.3Jaw/J
019376   FVB/N-Tg(tetO-MYC)36aBop/J
026278   FVB/N-Tg(tetO-Ube3a*1)1Svd/J
026279   FVB/N-Tg(tetO-Ube3a*2)884Svd/J
022938   FVB/N-Tg(tetO-Wnt5a)17Rva/J
003315   FVB/N-Tg(tetORo1-lacZ)3Conk/J
005076   NOD.Cg-Tg(tetO-EGFP/FADD)1Doi/DoiJ
006999   STOCK Dbttm1Geh Tg(Cebpb-tTA)5Bjd Tg(tetO-DBT)A1Geh/J
011004   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/J
011011   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm4(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/J
011013   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm5(tetO-Pou5f1,-Klf4,-Myc)Jae/J
017596   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb Tg(tetO-SMN2,-luc)#aAhmb/J
017597   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb Tg(tetO-SMN2,-luc)#bAhmb/J
025671   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(tetO-Fgf10)1Jaw/SpdlJ
024854   STOCK Tg(Camk2a-tTA)1Mmay Tg(tetO-MAPT*P301L)#Kha/J
008755   STOCK Tg(Ins2-rtTA)2Efr Tg(teto-DTA)1Gfi/J
012477   STOCK Tg(Myh6*/tetO-GCaMP2)1Mik/J
016572   STOCK Tg(Myh6/tetO-Gata4)1Jmol/J
014544   STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/J
014093   STOCK Tg(tetO-CHRM3*)1Blr/J
008790   STOCK Tg(tetO-DISC1*)1001Plet/J
008168   STOCK Tg(tetO-DTA)1Gfi/J
017755   STOCK Tg(tetO-GCAMP2)12iRyu/J
024509   STOCK Tg(tetO-Gata6)1Abl/J
016970   STOCK Tg(tetO-HCV)1Mlch/Mmjax
005104   STOCK Tg(tetO-HIST1H2BJ/GFP)47Efu/J
005699   STOCK Tg(tetO-Ipf1,EGFP)956.6Macd/J
005728   STOCK Tg(tetO-Ipf1,lacZ)958.1Macd/J
012441   STOCK Tg(tetO-LRRK2*G2019S)E3Cai/J
017918   STOCK Tg(tetO-MAML1*/EGFP)2Akar/J
017599   STOCK Tg(tetO-SMN2,-luc)#aAhmb/J
017600   STOCK Tg(tetO-SMN2,-luc)#bAhmb/J
012442   STOCK Tg(tetO-SNCA*A53T)E2Cai/J
006224   STOCK Tg(tetO-cre)1Jaw/J
017906   STOCK Tg(tetO-hop/EGFP,-COP4/mCherry)6Kftnk/J
012345   STOCK Tg(tetO-tdTomato,-Syp/EGFP*)1.1Luo/J
012449   STOCK Tg(teto-LRRK2)C7874Cai/J
View Strains carrying other alleles of tetO     (138 strains)

Additional Web Information

Visit the Alzheimer's Disease Mouse Model Resource site for helpful information on Alzheimer's Disease and research resources.

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.
Alzheimer Disease; AD
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Tg(tetO-APPSwInd)107Dbo/0

        involves: C3H/HeJ * C57BL/6J
  • no phenotypic analysis
  • *normal* no phenotypic analysis
    • no analysis of single transgenic mice provided   (MGI Ref ID J:109829)

The following phenotype relates to a compound genotype created using this strain.
Contact JAX® Services jaxservices@jax.org for customized breeding options.

Tg(Camk2a-tTA)1Mmay/0 Tg(tetO-APPSwInd)107Dbo/0

        involves: C3H/HeJ * C57BL/6 * CBA
  • nervous system phenotype
  • abnormal astrocyte morphology
    • activated astrocytes are found near plaques in all affected mice glial pathology is more severe in older mice   (MGI Ref ID J:109829)
    • if transgene expression is suppressed with doxycycline treatment, pathology does not progress in severity   (MGI Ref ID J:109829)
  • abnormal dentate gyrus morphology
    • mice exhibit a progressive neuronal atrophy that is most pronounced in the granule cell layer of hippocampal dentate gyrus   (MGI Ref ID J:185792)
  • abnormal nervous system physiology
    • mice produce transgenic APP protein at 10- to 30-fold over endogenous App levels   (MGI Ref ID J:109829)
    • sensitivity of transgene suppression by doxycycline is intermediate between mice of line 885 and line 102   (MGI Ref ID J:109829)
    • CNS inflammation
      • neuritic pathology is observed around plaques; neuritic pathology is more severe in older mice   (MGI Ref ID J:109829)
      • if transgene expression is suppressed with doxycycline treatment, pathology does not progress in severity   (MGI Ref ID J:109829)
  • amyloid beta deposits
    • doxycycline-mediated suppression of transgenic APPSwInd synthesis leads to parallel reductions of amyloid beta peptide levels   (MGI Ref ID J:109829)
    • early onset amyloid formation is observed, with plaques observed as early as 8 weeks of age in mice receiving no doxycycline (DOX) treatment   (MGI Ref ID J:109829)
    • plaques are restricted to the forebrain, including the cortex, hippocampus, olfactory bulb, and striatum; by 6 months, amyloid burden covers large cortical and hippocampal areas   (MGI Ref ID J:109829)
    • first observed plaques are fibrillar-core deposits; in 6 month old animals, diffuse plaques are apparent and these are abundant at 9 months, while in 9-12 month-old mice, plaques are visible in the thalamus   (MGI Ref ID J:109829)
    • no lesions are observed in the cerebellum or brain stem   (MGI Ref ID J:109829)
    • animals receiving no treatment display moderate amyloid pathology at 6 months, which progresses to a severe amyloid burden by 9 months   (MGI Ref ID J:109829)
    • mice raised for 6 months with no (DOX) treatment, followed by 3 or 6 months of DOX treatment show similar pathology to untreated 6-month old animals, despite relatively long lesion clearance times   (MGI Ref ID J:109829)
  • hippocampal neuron degeneration
    • mice exhibit a progressive neuronal atrophy that is most pronounced in the granule cell layer of hippocampal dentate gyrus   (MGI Ref ID J:185792)
    • however, when mice are reared on doxycycline, cell loss is not observed   (MGI Ref ID J:185792)
  • neurofibrillary tangles
    • first visible plaques are fibrillary-cored deposits   (MGI Ref ID J:109829)
  • behavior/neurological phenotype
  • abnormal circadian rhythm
    • all animals raised with doxycycline have altered circadian rhythms with less distinction between day- and nighttime activity levels   (MGI Ref ID J:109829)
  • abnormal locomotor activation
    • hyperactive behavior is partially reversed in some mice by 1 month of transgene suppression starting at 4-5 months of age   (MGI Ref ID J:109829)
    • hyperactivity
      • untreated mice show hyperactivity, often running in circles around the perimeter of cages   (MGI Ref ID J:109829)
      • similar patterns of activity are observed in Morris water maze, with repetitive swim patterns seen in radial water maze swim test   (MGI Ref ID J:109829)
      • hyperactive phenotype penetrance is ~100%   (MGI Ref ID J:109829)
      • untreated mice show 10-fold more ambulatory activity during the dark phase; even in light phase, activity is several-fold increased compared to wild-type controls; this activity is completely abolished in mice raised on doxycycline   (MGI Ref ID J:109829)
  • immune system phenotype
  • CNS inflammation
    • neuritic pathology is observed around plaques; neuritic pathology is more severe in older mice   (MGI Ref ID J:109829)
    • if transgene expression is suppressed with doxycycline treatment, pathology does not progress in severity   (MGI Ref ID J:109829)
  • homeostasis/metabolism phenotype
  • amyloid beta deposits
    • doxycycline-mediated suppression of transgenic APPSwInd synthesis leads to parallel reductions of amyloid beta peptide levels   (MGI Ref ID J:109829)
    • early onset amyloid formation is observed, with plaques observed as early as 8 weeks of age in mice receiving no doxycycline (DOX) treatment   (MGI Ref ID J:109829)
    • plaques are restricted to the forebrain, including the cortex, hippocampus, olfactory bulb, and striatum; by 6 months, amyloid burden covers large cortical and hippocampal areas   (MGI Ref ID J:109829)
    • first observed plaques are fibrillar-core deposits; in 6 month old animals, diffuse plaques are apparent and these are abundant at 9 months, while in 9-12 month-old mice, plaques are visible in the thalamus   (MGI Ref ID J:109829)
    • no lesions are observed in the cerebellum or brain stem   (MGI Ref ID J:109829)
    • animals receiving no treatment display moderate amyloid pathology at 6 months, which progresses to a severe amyloid burden by 9 months   (MGI Ref ID J:109829)
    • mice raised for 6 months with no (DOX) treatment, followed by 3 or 6 months of DOX treatment show similar pathology to untreated 6-month old animals, despite relatively long lesion clearance times   (MGI Ref ID J:109829)

Tg(Camk2a-tTA)1Mmay/0 Tg(tetO-APPSwInd)107Dbo/0

        (FVB/NJ x B6.Cg-Tg(tetO-APPSwInd)107Dbo Tg(Camk2a-tTA)1Mmay)F1
  • behavior/neurological phenotype
  • *normal* behavior/neurological phenotype
    • bitransgenic (off-DOX) males perform like wild-type males in Plus water maze apparatus, swimming abilities, and latency to find platform   (MGI Ref ID J:195259)
    • abnormal long term spatial reference memory
      • in a test of long-term reference memory, radial arm water maze (RAWM) administered after a 24 hour delay, bi-transgenic males (off-DOX) performed at the level of chance with a significantly increased number of errors compared to wild type   (MGI Ref ID J:195259)
      • bi-transgenic mice (on-DOX) perform similar to non-transgenic controls in RAWM   (MGI Ref ID J:195259)
      • in a test of cognitive flexibility, as assessed by changing the water maze escape platform position daily, bi-transgenic males (on-DOX) continue to visit the original location significantly more frequently than non-transgenic controls, however, in subsequent sessions the error rate becomes similar to non-transgenic controls   (MGI Ref ID J:195259)
    • abnormal spatial working memory
      • 12.5 month old bi-transgenic males (off-DOX) exhibit significantly less preference for exploring the new arm of the two trial Y maze (a test of short term spatial memory)   (MGI Ref ID J:195259)
      • 12.5 month old bi-transgenic males (on-DOX) exhibit a preference for the new arm   (MGI Ref ID J:195259)
      • 12.5 month old bi-transgenic males (off-DOX) exhibit improved performance after successive trials, but an increased number of errors compared to wild-type non-Tg and on-DOX Tg controls in the radial arm water maze (RAWM), a test of long term spatial memory   (MGI Ref ID J:195259)
  • nervous system phenotype
  • amyloid beta deposits
    • found in the CA layer of the hippocampus in off-DOX and on-DOX (for 7 days) 23 month old bi-transgenic males, however, after 5 weeks on doxycycline APP/amyloid beta (as assessed by mAb 6E10) immunoreactivity disappears   (MGI Ref ID J:195259)
    • a low level of mobile, water-extractable Abeta42 is present in bitransgenic males treated with DOX for up to 4 weeks   (MGI Ref ID J:195259)
  • homeostasis/metabolism phenotype
  • amyloid beta deposits
    • found in the CA layer of the hippocampus in off-DOX and on-DOX (for 7 days) 23 month old bi-transgenic males, however, after 5 weeks on doxycycline APP/amyloid beta (as assessed by mAb 6E10) immunoreactivity disappears   (MGI Ref ID J:195259)
    • a low level of mobile, water-extractable Abeta42 is present in bitransgenic males treated with DOX for up to 4 weeks   (MGI Ref ID J:195259)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Neurobiology Research
Alzheimer's Disease
      strains expressing mutant APP
Neurodegeneration
Tet Expression System
      tTA/rtTA Responsive Strains

Research Tools
Neurobiology Research
      Tetop Tet System
Tet Expression Systems
      tTA/rtTA Responsive Strains

Tg(tetO-APPSwInd)107Dbo related

Neurobiology Research
Alzheimer's Disease
      inducible models

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Tg(tetO-APPSwInd)107Dbo
Allele Name transgene insertion 107, David R Borchelt
Allele Type Transgenic (Inducible, Inserted expressed sequence)
Common Name(s) tet-APPswe/ind line 107;
Mutation Made ByDr. David Borchelt,   University of Florida
Strain of Origin(C57BL/6J x C3H/HeJ)F1
Expressed Gene APP695, amyloid beta (A4) precursor protein (chimeric), mouse/human chimera
Promoter tetO, tet operator,
Molecular Note The mouse amyloid beta (A4) precursor protein (APP) sequence was modified to contain a humanized amyloid-beta (Abeta) domain. This mouse/human chimeric APP (mo/huAPP695 or APP695) was mutated to incorporate the Swedish (KM570/571NL) and Indiana (V617F) APP mutations associated with Alzheimer's disease. This APP695swe/ind sequence was placed downstream of the tetracycline-responsive (TRE or tetO) promoter and mouse prion protein exons 1-2. Line 107 was established and most thoroughly studied. [MGI Ref ID J:109829]
 
 

Genotyping

Genotyping Information

Genotyping Protocols

Tg(APP), Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Jankowsky JL; Slunt HH; Gonzales V; Savonenko AV; Wen JC; Jenkins NA; Copeland NG; Younkin LH; Lester HA; Younkin SG; Borchelt DR. 2005. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med 2(12):e355. [PubMed: 16279840]  [MGI Ref ID J:109829]

Additional References

Tg(tetO-APPSwInd)107Dbo related

Borchelt DR; Davis J; Fischer M; Lee MK; Slunt HH; Ratovitsky T; Regard J; Copeland NG; Jenkins NA; Sisodia SS; Price DL. 1996. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal 13(6):159-63. [PubMed: 9117892]  [MGI Ref ID J:80782]

Han HJ; Allen CC; Buchovecky CM; Yetman MJ; Born HA; Marin MA; Rodgers SP; Song BJ; Lu HC; Justice MJ; Probst FJ; Jankowsky JL. 2012. Strain background influences neurotoxicity and behavioral abnormalities in mice expressing the tetracycline transactivator. J Neurosci 32(31):10574-86. [PubMed: 22855807]  [MGI Ref ID J:185792]

Melnikova T; Fromholt S; Kim H; Lee D; Xu G; Price A; Moore BD; Golde TE; Felsenstein KM; Savonenko A; Borchelt DR. 2013. Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. J Neurosci 33(9):3765-79. [PubMed: 23447589]  [MGI Ref ID J:195259]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Colony Maintenance

Breeding & HusbandryWhen maintained as a live colony, hemizygous mice are bred to C57BL/6J or wildtype siblings.

Pricing and Purchasing

Supply Notes


Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Strain(s) not available to companies or for-profit entities.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)